Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice

James O. McNamara, Despina Kolonias, Fernando Pastor, Robert S. Mittler, Lieping Chen, Paloma H. Giangrande, Bruce Sullenger, Eli Gilboa

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

4-1BB is a major costimulatory receptor that promotes the survival and expansion of activated T cells. Administration of agonistic anti-4-1BB Abs has been previously shown to enhance tumor immunity in mice. Abs are cell-based products posing significant cost, manufacturing, and regulatory challenges. Aptamers are oligonucleotide-based ligands that exhibit specificity and avidity comparable to, or exceeding, that of Abs. To date, various aptamers have been shown to inhibit the function of their cognate target. Here, we have described the development of an aptamer that binds 4-1BB expressed on the surface of activated mouse T cells and shown that multivalent configurations of the aptamer costimulated T cell activation in vitro and mediated tumor rejection in mice. Because aptamers can be chemically synthesized, manufacturing and the regulatory approval process should be substantially simpler and less costly than for Abs. Agonistic aptamers could therefore represent a superior alternative to Abs for the therapeutic manipulation of the immune system.

Original languageEnglish
Pages (from-to)376-386
Number of pages11
JournalJournal of Clinical Investigation
Volume118
Issue number1
DOIs
StatePublished - Jan 2 2008

Fingerprint

T-Lymphocytes
Growth
Neoplasms
Oligonucleotides
Immune System
Immunity
Ligands
Costs and Cost Analysis
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Medicine(all)

Cite this

McNamara, J. O., Kolonias, D., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., ... Gilboa, E. (2008). Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. Journal of Clinical Investigation, 118(1), 376-386. https://doi.org/10.1172/JCI33365

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. / McNamara, James O.; Kolonias, Despina; Pastor, Fernando; Mittler, Robert S.; Chen, Lieping; Giangrande, Paloma H.; Sullenger, Bruce; Gilboa, Eli.

In: Journal of Clinical Investigation, Vol. 118, No. 1, 02.01.2008, p. 376-386.

Research output: Contribution to journalArticle

McNamara, JO, Kolonias, D, Pastor, F, Mittler, RS, Chen, L, Giangrande, PH, Sullenger, B & Gilboa, E 2008, 'Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice', Journal of Clinical Investigation, vol. 118, no. 1, pp. 376-386. https://doi.org/10.1172/JCI33365
McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. Journal of Clinical Investigation. 2008 Jan 2;118(1):376-386. https://doi.org/10.1172/JCI33365
McNamara, James O. ; Kolonias, Despina ; Pastor, Fernando ; Mittler, Robert S. ; Chen, Lieping ; Giangrande, Paloma H. ; Sullenger, Bruce ; Gilboa, Eli. / Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. In: Journal of Clinical Investigation. 2008 ; Vol. 118, No. 1. pp. 376-386.
@article{439b7180ed544ba2974620c396d50842,
title = "Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice",
abstract = "4-1BB is a major costimulatory receptor that promotes the survival and expansion of activated T cells. Administration of agonistic anti-4-1BB Abs has been previously shown to enhance tumor immunity in mice. Abs are cell-based products posing significant cost, manufacturing, and regulatory challenges. Aptamers are oligonucleotide-based ligands that exhibit specificity and avidity comparable to, or exceeding, that of Abs. To date, various aptamers have been shown to inhibit the function of their cognate target. Here, we have described the development of an aptamer that binds 4-1BB expressed on the surface of activated mouse T cells and shown that multivalent configurations of the aptamer costimulated T cell activation in vitro and mediated tumor rejection in mice. Because aptamers can be chemically synthesized, manufacturing and the regulatory approval process should be substantially simpler and less costly than for Abs. Agonistic aptamers could therefore represent a superior alternative to Abs for the therapeutic manipulation of the immune system.",
author = "McNamara, {James O.} and Despina Kolonias and Fernando Pastor and Mittler, {Robert S.} and Lieping Chen and Giangrande, {Paloma H.} and Bruce Sullenger and Eli Gilboa",
year = "2008",
month = "1",
day = "2",
doi = "10.1172/JCI33365",
language = "English",
volume = "118",
pages = "376--386",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice

AU - McNamara, James O.

AU - Kolonias, Despina

AU - Pastor, Fernando

AU - Mittler, Robert S.

AU - Chen, Lieping

AU - Giangrande, Paloma H.

AU - Sullenger, Bruce

AU - Gilboa, Eli

PY - 2008/1/2

Y1 - 2008/1/2

N2 - 4-1BB is a major costimulatory receptor that promotes the survival and expansion of activated T cells. Administration of agonistic anti-4-1BB Abs has been previously shown to enhance tumor immunity in mice. Abs are cell-based products posing significant cost, manufacturing, and regulatory challenges. Aptamers are oligonucleotide-based ligands that exhibit specificity and avidity comparable to, or exceeding, that of Abs. To date, various aptamers have been shown to inhibit the function of their cognate target. Here, we have described the development of an aptamer that binds 4-1BB expressed on the surface of activated mouse T cells and shown that multivalent configurations of the aptamer costimulated T cell activation in vitro and mediated tumor rejection in mice. Because aptamers can be chemically synthesized, manufacturing and the regulatory approval process should be substantially simpler and less costly than for Abs. Agonistic aptamers could therefore represent a superior alternative to Abs for the therapeutic manipulation of the immune system.

AB - 4-1BB is a major costimulatory receptor that promotes the survival and expansion of activated T cells. Administration of agonistic anti-4-1BB Abs has been previously shown to enhance tumor immunity in mice. Abs are cell-based products posing significant cost, manufacturing, and regulatory challenges. Aptamers are oligonucleotide-based ligands that exhibit specificity and avidity comparable to, or exceeding, that of Abs. To date, various aptamers have been shown to inhibit the function of their cognate target. Here, we have described the development of an aptamer that binds 4-1BB expressed on the surface of activated mouse T cells and shown that multivalent configurations of the aptamer costimulated T cell activation in vitro and mediated tumor rejection in mice. Because aptamers can be chemically synthesized, manufacturing and the regulatory approval process should be substantially simpler and less costly than for Abs. Agonistic aptamers could therefore represent a superior alternative to Abs for the therapeutic manipulation of the immune system.

UR - http://www.scopus.com/inward/record.url?scp=38149096315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149096315&partnerID=8YFLogxK

U2 - 10.1172/JCI33365

DO - 10.1172/JCI33365

M3 - Article

VL - 118

SP - 376

EP - 386

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -